A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Adding metastasis-directed therapy (MDT) to standard of care was tied to improvements in several survival endpoints in oligometastatic prostate cancer, a recent analysis suggests.

While some of his allies have lamented that Biden's legacy as president has been reduced to questions of his declining health and mental acuity, many Democrats are still bitter about Biden's 2024 ...

Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," ...

MDT associated with improved progression-free, radiographic progression-free, castration resistance-free survival.